Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Buildings (2016 - 2019)

Myriad Genetics (MYGN) has disclosed Buildings for 5 consecutive years, with $18.2 million as the latest value for Q3 2019.

  • On a quarterly basis, Buildings fell 3.7% to $18.2 million in Q3 2019 year-over-year; TTM through Sep 2019 was $18.2 million, a 3.7% decrease, with the full-year FY2019 number at $18.8 million, down 2.59% from a year prior.
  • Buildings was $18.2 million for Q3 2019 at Myriad Genetics, down from $18.8 million in the prior quarter.
  • In the past five years, Buildings ranged from a high of $20.5 million in Q1 2018 to a low of $16.1 million in Q4 2016.
  • A 5-year average of $18.2 million and a median of $18.2 million in 2015 define the central range for Buildings.
  • Peak YoY movement for Buildings: fell 13.3% in 2017, then grew 25.77% in 2018.
  • Myriad Genetics' Buildings stood at $17.3 million in 2015, then decreased by 6.94% to $16.1 million in 2016, then increased by 22.98% to $19.8 million in 2017, then decreased by 4.55% to $18.9 million in 2018, then decreased by 3.7% to $18.2 million in 2019.
  • Per Business Quant, the three most recent readings for MYGN's Buildings are $18.2 million (Q3 2019), $18.8 million (Q2 2019), and $18.6 million (Q1 2019).